Imaging Control Study, 3D Echo, MR and RHC.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

12 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional echocardiography in order to optimize their specific therapy.

The hypothesis is that the increased use of modern imaging guided tools is essential for the follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Therapy of Pulmonary Arterial Hypertension

NCT00909337

Pulmonary Hypertension Systemic Sclerosis

COMPLETED NA

Endothelial Function in Patients With Pulmonary Arterial Hypertension

NCT01317134

Hypertension, Pulmonary Pulmonary Arterial Hypertension Pathophysiology +1 more

COMPLETED NA

Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen

NCT03135860

COPD Pulmonary Hypertension Chronic Obstructive Pulmonary Disease

TERMINATED EARLY_PHASE1

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345

Pulmonary Hypertension Pulmonary Arterial Hypertension

NOT_YET_RECRUITING PHASE2

Assessing the Utility of Submaximal CPET in Treatment Management of PAH

NCT05977933

Pulmonary Arterial Hypertension

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is not possible to perform a magnetic resonance imaging in all patients and as a result echocardiography is not only done at screening but also during the follow up. The imaging technologies made a great progress in the last few years and enable a better assessment of the haemodynamic parameters in our days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension WHO Group I

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3D echocardiography

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>17
* pulmonary arterial hypertension WHO group I who are going to start a therapy with prostanoid
* written informed consent
* Prostanoid naive
* no change of the pulmonary arterial hypertension therapy within 3 weeks of inclusion into the study

Exclusion Criteria

* pregnancy and lactation period
* Women of childbearing potential who do not use an effective and secure method for birth control
* severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
* liver insufficiency Child C
* life expectancy shorter than the course of the study (for example because of a malignant disease)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No